Idhifa® (enasidenib) – New orphan drug approval
August 1, 2017 – The FDA announced the approval of Celgene’s Idhifa (enasidenib), for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Top